亚太药业
(002370)
| 流通市值：28.04亿 | | | 总市值：28.04亿 |
| 流通股本：7.46亿 | | | 总股本：7.46亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 64,550,537.91 | 405,174,661.29 | 306,835,789.08 | 221,933,271.08 |
| 营业收入 | 64,550,537.91 | 405,174,661.29 | 306,835,789.08 | 221,933,271.08 |
| 二、营业总成本 | 70,881,335.56 | 430,113,073.56 | 327,680,456.45 | 228,077,115.52 |
| 营业成本 | 44,313,204.73 | 278,889,830.7 | 211,419,192.11 | 151,267,862.46 |
| 税金及附加 | 1,190,216.58 | 6,385,223.42 | 4,651,222.77 | 2,963,984.05 |
| 销售费用 | 9,396,728.76 | 57,125,902.79 | 44,107,484.18 | 29,538,330.53 |
| 管理费用 | 14,465,490.73 | 53,425,235.46 | 40,838,470.04 | 25,687,687.06 |
| 研发费用 | 2,114,765.79 | 14,640,524.49 | 10,253,111.79 | 7,145,935.77 |
| 财务费用 | -599,071.03 | 19,646,356.7 | 16,410,975.56 | 11,473,315.65 |
| 其中:利息费用 | 2,464,220.63 | 30,590,222.13 | 26,373,771.94 | 17,966,682.99 |
| 其中:利息收入 | 3,076,676.55 | 11,301,468.97 | 7,048,156.62 | 6,500,306.62 |
| 加:公允价值变动收益 | -1,408,944.07 | 1,638,089.72 | 1,045,841.69 | -2,765,571.79 |
| 加:投资收益 | - | 53,816,793.8 | 15,853,845.06 | 14,683,325.57 |
| 资产处置收益 | - | -7,367.1 | - | - |
| 资产减值损失(新) | -2,370,685.85 | -5,563,928.48 | -1,867,352.1 | -1,867,352.1 |
| 信用减值损失(新) | 420,870.66 | -32,192.56 | 83,839.38 | 148,419.83 |
| 其他收益 | 1,685,011.21 | 3,242,495.18 | 2,525,907.61 | 1,112,719.51 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -8,004,545.7 | 28,155,478.29 | -3,202,585.73 | 5,167,696.58 |
| 加:营业外收入 | 1,416.11 | 11,439,832.7 | 122,290 | 115,000 |
| 减:营业外支出 | 11,424.73 | 5,109,816.2 | 222,358.49 | 222,358.49 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -8,014,554.32 | 34,485,494.79 | -3,302,654.22 | 5,060,338.09 |
| 减:所得税费用 | -211,341.61 | 245,713.46 | 156,876.25 | -414,835.77 |
| 六、净利润 | -7,803,212.71 | 34,239,781.33 | -3,459,530.47 | 5,475,173.86 |
| 持续经营净利润 | -7,803,212.71 | 34,239,781.33 | -3,459,530.47 | 5,475,173.86 |
| 归属于母公司股东的净利润 | -7,803,212.71 | 34,239,781.33 | -3,459,530.47 | 5,475,173.86 |
| (一)基本每股收益 | -0.01 | 0.05 | -0.01 | 0.01 |
| (二)稀释每股收益 | -0.01 | 0.05 | -0.01 | 0.01 |
| 八、其他综合收益 | - | 598,381.19 | 598,381.19 | 598,381.19 |
| 归属于母公司股东的其他综合收益 | - | 598,381.19 | 598,381.19 | 598,381.19 |
| 九、综合收益总额 | -7,803,212.71 | 34,838,162.52 | -2,861,149.28 | 6,073,555.05 |
| 归属于母公司股东的综合收益总额 | -7,803,212.71 | 34,838,162.52 | -2,861,149.28 | 6,073,555.05 |
| 公告日期 | 2025-04-30 | 2025-04-25 | 2024-10-31 | 2024-08-24 |
| 审计意见(境内) | | 标准无保留意见 | | |